Lv3
278 积分 2022-07-12 加入
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
16小时前
已完结
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
19小时前
已完结
Photostability of Topoisomerase I Inhibitor Conjugated IgG1 Antibody–Drug Conjugates: Characterization Study and Degradation Mechanism Analysis
8天前
已完结
Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis
12天前
已完结
Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors
23天前
已完结
Evaluation of Double Self-Immolative Linker-Based Antibody–Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential
1个月前
已完结
Cathepsin B-Responsive Phosphatidylinositol 3-Kinase (PI3K) Prodrug for the Treatment of Pulmonary Fibrosis
1个月前
已完结
FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
1个月前
已完结
Radiation-Activated Resiquimod Prodrug Nanomaterials for Enhancing Immune Checkpoint Inhibitor Therapy
1个月前
已完结
Azide‐Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy
1个月前
已完结
皖公网安备34019202002308
